Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9614470 | 0.86 | TSHR (0.50) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL22034596 | 0.81 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL1585013 | 0.81 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL22034670 | 0.79 | TSHR (0.43) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL22639014 | 0.79 | TSHR (0.43) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL1071833 | 0.79 | TSHR (0.43) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL13992743 | 0.77 | TSHR (0.42) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL10911354 | 0.77 | TSHR (0.53) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL27935336 | 0.75 | TSHR (0.40) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL10201143 | 0.74 | TSHR (0.50) | TSHRTP53TDP1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903102-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |